<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Faron Pharmaceuticals Oy — News on 6ix</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy</link>
<description>Latest news and press releases for Faron Pharmaceuticals Oy on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 12:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/faron-pharmaceuticals-oy" rel="self" type="application/rss+xml" />
<item>
<title>Faron Pharmaceuticals Ltd: Remaining offer sh...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-remaining-offer-sh</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-remaining-offer-sh</guid>
<pubDate>Tue, 14 Apr 2026 12:15:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd. has registered the remaining 41,944,771 offer shares with the Finnish Trade Register, bringing the total registered shares to 203,045,511, with 199,514,938 voting rights after accounting for treasury shares. These remaining shares are expected to be available in investors' book-entry accounts around April 15, 2026, and trading on Nasdaq First North Growth Market Finland and AIM is anticipated to commence on or about the same date.
Disclaimer*</description>
</item>
<item>
<title>Notice of Faron Pharmaceuticals LTD's Annual General Meeting</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/notice-of-faron-pharmaceuticals-ltds-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/notice-of-faron-pharmaceuticals-ltds-annual-general-meeting</guid>
<pubDate>Fri, 10 Apr 2026 13:47:00 GMT</pubDate>
<description>TURKU, FI / ACCESS Newswire / April 10, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Shareholders of Faron Pharmaceuticals Ltd (the "Company") are notified of the Annual General Meeting (the "AGM") to be held on 4 May 2026 at 10:00 a.m. EEST ...</description>
</item>
<item>
<title>Faron publishes final results of its EUR 40.1...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-publishes-final-results-of-its-eur-401</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-publishes-final-results-of-its-eur-401</guid>
<pubDate>Thu, 09 Apr 2026 17:25:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd. has announced the final results of its EUR 40.1 million rights offering, which saw approximately 52.33% of the offered shares subscribed for, raising gross proceeds of EUR 40.1 million and net proceeds of approximately EUR 32.8 million. These funds will be used to strengthen the company's financial position, advance a Phase II trial for myelodysplastic syndrome with bexmarilimab, and accelerate bexmarilimab development through investigator-initiated trials. The total n</description>
</item>
<item>
<title>Inside Information: Faron publishes prelimina...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/inside-information-faron-publishes-prelimina</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/inside-information-faron-publishes-prelimina</guid>
<pubDate>Wed, 08 Apr 2026 14:15:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd. has announced preliminary results for its rights offering, which raised approximately EUR 40.1 million in gross proceeds and EUR 32.8 million in net proceeds. The offering saw subscriptions for 52.33% of the offered shares, with the funds earmarked for strengthening the company's financial position, conducting a Phase II trial for high-risk myelodysplastic syndrome with bexmarilimab, and accelerating bexmarilimab development through investigator-initiated trials. This </description>
</item>
<item>
<title>Suspension - Faron Pharmaceuticals Oy</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/suspension-faron-pharmaceuticals-oy</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/suspension-faron-pharmaceuticals-oy</guid>
<pubDate>Mon, 30 Mar 2026 06:30:00 GMT</pubDate>
<description>Trading in Faron Pharmaceuticals Oy's subscription rights, nil paid, was temporarily suspended on AIM effective from 7:30 am on March 30, 2026, at the company's request, pending a forthcoming announcement.
Disclaimer*</description>
</item>
<item>
<title>Faron Pharmaceuticals Ltd: Faron appoints new...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-faron-appoints-new</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-faron-appoints-new</guid>
<pubDate>Thu, 26 Mar 2026 07:00:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd. has appointed Heikki Jouttijärvi as Chief Technical Officer, bringing extensive experience in biopharma manufacturing and commercial operations, most recently from Adverum Biotechnologies. This appointment is considered valuable as Faron progresses its investigational immunotherapy, bexmarilimab, towards a Phase IIb trial in HR MDS, aiming to enhance immune system response against cancer by targeting macrophage function.
Disclaimer*</description>
</item>
<item>
<title>FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMP...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-holdings-in-comp</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-holdings-in-comp</guid>
<pubDate>Wed, 11 Mar 2026 08:00:00 GMT</pubDate>
<description>Varma Mutual Pension Insurance Company has reduced its holding in Faron Pharmaceuticals Ltd, crossing a threshold on February 11, 2026. The notification indicates a decrease in holdings, with Varma's voting rights now standing at 2.2%, representing 2,633,674 voting rights. This is a decrease from their previous notification where they held 4.16% of the voting rights.
Disclaimer*</description>
</item>
<item>
<title>Inside Information: Faron publishes the terms...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/inside-information-faron-publishes-the-terms</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/inside-information-faron-publishes-the-terms</guid>
<pubDate>Tue, 10 Mar 2026 07:48:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd. is launching a rights offering to raise approximately EUR 40 million, with a subscription price of EUR 0.50 per share, to fund a Phase II trial for bexmarilimab in high-risk myelodysplastic syndrome and support investigator-initiated trials. The offering is fully covered by cornerstone investments and subscription commitments totaling EUR 11.76 million, along with guarantees covering the remainder, extending the company's cash runway to November 2027. The subscription </description>
</item>
<item>
<title>Update to Faron's Financial Calendar and Date of the Annual General Meeting in 2026</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/update-to-farons-financial-calendar-and-date-of-the-annual-general-meeting-in-2026</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/update-to-farons-financial-calendar-and-date-of-the-annual-general-meeting-in-2026</guid>
<pubDate>Mon, 09 Mar 2026 18:00:00 GMT</pubDate>
<description>TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces an update for the Company's ...</description>
</item>
<item>
<title>Update to Faron’s Financial Calendar and date...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/update-to-farons-financial-calendar-and-date</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/update-to-farons-financial-calendar-and-date</guid>
<pubDate>Mon, 09 Mar 2026 17:45:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd. has updated its 2026 financial calendar, rescheduling its Annual General Meeting to May 4, 2026, from the previously announced March 30, 2026 date. The publication of the company's half-year financial report for the period ending June 30, 2026, remains unchanged and is scheduled for August 26, 2026.
Disclaimer*</description>
</item>
<item>
<title>CORRECTION: Faron Pharmaceuticals Ltd's Annual Report 2025 published</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/correction-faron-pharmaceuticals-ltds-annual-report-2025-published</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/correction-faron-pharmaceuticals-ltds-annual-report-2025-published</guid>
<pubDate>Wed, 04 Mar 2026 17:05:00 GMT</pubDate>
<description>The Annual Report 2025 published did not contain the auditor's report. This has been corrected in this version. TURKU, FINLAND / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Faron Pharmaceuticals Ltd. (AIM:FARN)(First ...</description>
</item>
<item>
<title>Correction: Faron Pharmaceuticals Ltd’s Annua...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/correction-faron-pharmaceuticals-ltds-annua</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/correction-faron-pharmaceuticals-ltds-annua</guid>
<pubDate>Wed, 04 Mar 2026 16:45:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd. has issued a correction to its Annual Report 2025, originally published on March 4, 2026, to include the missing auditor's report. An updated version of the Annual Report 2025, containing the full auditor's report, is now available as an attachment to the announcement and on the company's website in both English and Finnish. This correction is a procedural update and does not appear to involve any new financial figures or changes to the company's reported performance f</description>
</item>
<item>
<title>Faron Pharmaceuticals Ltd's Annual Report 2025 Published</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltds-annual-report-2025-published</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltds-annual-report-2025-published</guid>
<pubDate>Wed, 04 Mar 2026 07:35:00 GMT</pubDate>
<description>TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today published the Annual Report for 2025. The Annual ...</description>
</item>
<item>
<title>Faron's Financial Statements Release 1 January to 31 December 2025</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/farons-financial-statements-release-1-january-to-31-december-2025</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/farons-financial-statements-release-1-january-to-31-december-2025</guid>
<pubDate>Wed, 04 Mar 2026 07:30:00 GMT</pubDate>
<description>TURKU, FI / ACCESS Newswire / March 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based immunotherapy under development Figures in parentheses refer ...</description>
</item>
<item>
<title>Faron Pharmaceuticals Ltd’s Annual Report 202...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltds-annual-report-202</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltds-annual-report-202</guid>
<pubDate>Wed, 04 Mar 2026 07:15:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd has published its Annual Report for 2025, which includes the Report of the Board of Directors, Financial Statements, and Remuneration Report. The report details the company's focus on novel immunotherapies for cancer, specifically mentioning the ongoing Phase I/II clinical trial of bexmarilimab in combination with standard of care for acute myeloid leukemia and myelodysplastic syndrome. The company's lead asset, bexmarilimab, targets Clever-1 to reprogram the tumor micr</description>
</item>
<item>
<title>Faron’s Financial Statements Release 1 Januar...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/farons-financial-statements-release-1-januar</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/farons-financial-statements-release-1-januar</guid>
<pubDate>Wed, 04 Mar 2026 07:00:00 GMT</pubDate>
<description>Faron Pharmaceuticals reported steady progress in 2025 with its lead asset bexmarilimab, securing EUR 12 million from a private placement and an additional EUR 25 million from convertible bonds, while research and development expenses increased to EUR 12.7 million and the operating loss was EUR 19.0 million. The company received positive orphan drug designations from the EMA and FDA for bexmarilimab and had a productive End of Phase 2 meeting with the FDA regarding its clinical development plan.</description>
</item>
<item>
<title>Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-results-of-the-extraordinary-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-results-of-the-extraordinary-general-meeting</guid>
<pubDate>Mon, 02 Mar 2026 10:20:00 GMT</pubDate>
<description>TURKU, FI / ACCESS Newswire / March 2, 2026 / Faron Pharmaceuticals Ltd (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the ...</description>
</item>
<item>
<title>Faron Pharmaceuticals Ltd: Results of the Ext...</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-results-of-the-ext</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-pharmaceuticals-ltd-results-of-the-ext</guid>
<pubDate>Mon, 02 Mar 2026 10:00:00 GMT</pubDate>
<description>Faron Pharmaceuticals Ltd announced that its extraordinary general meeting approved the Board of Directors' proposal to authorize a rights offering of up to 80,000,000 new shares, valid until June 30, 2026, with unsubscribed shares potentially offered to other shareholders or third parties. This authorization does not revoke previous share issuance authorities. The company is developing bexmarilimab, an immunotherapy targeting Clever-1 for hematological cancers, currently in a Phase I/II clinica</description>
</item>
<item>
<title>Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-and-city-of-hope-in-process-of-developing-a-phase-ii-investigator-initiated-trial-of-bexmarilimab-in-relapsedrefractory-mds</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/faron-and-city-of-hope-in-process-of-developing-a-phase-ii-investigator-initiated-trial-of-bexmarilimab-in-relapsedrefractory-mds</guid>
<pubDate>Mon, 02 Mar 2026 07:15:00 GMT</pubDate>
<description>Building on the clinical results of the BEXMAB trial, the IIT aims to evaluate bexmarilimab with an oral HMA backbone to further strengthen evidence of its efficacy in research participants with high-risk myelodysplastic syndrome (HR MDS) TURKU, FI ...</description>
</item>
<item>
<title>Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026</title>
<link>https://6ix.com/company/faron-pharmaceuticals-oy/news/farons-bexmarilimab-data-accepted-for-poster-presentation-at-the-bsh-annual-scientific-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/faron-pharmaceuticals-oy/news/farons-bexmarilimab-data-accepted-for-poster-presentation-at-the-bsh-annual-scientific-meeting-2026</guid>
<pubDate>Mon, 23 Feb 2026 07:20:00 GMT</pubDate>
<description>TURKU, FI / ACCESS Newswire / February 23, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces that data from its Phase I/II ...</description>
</item>
</channel>
</rss>